• Juanjuan Zhao, Meirong Wu, Zhifeng Li, Sheng Su, Yin Wen, Litian Zhang, and Yuhua Li.
• Department of Hematology, Zhujiang Hospital, Southern Medical University, No. 253, Middle Gongye Avenue, Guangzhou, 510282, Guangdong, People's Republic of China.
• Ann. Hematol. 2020 Aug 1; 99 (8): 1681-1699.

AbstractChimeric antigen receptor (CAR)-based immunotherapy has achieved dramatic success in the treatment of B cell malignancies, based on the summary of current research data, and has shown good potential in early phase cancer clinical trials. Modified constructs are being optimized to recognize and destroy tumor cells more effectively. By targeting the proper B-lineage-specific antigens such as CD19 and CD20, adoptive immunotherapy has demonstrated promising clinical results and already plays a role in the treatment of several lymphoid malignancies, which highlights the importance of target selection for other CAR therapies. The high efficacy of CAR-T cells has resulted in the approval of anti-CD19-directed CAR-T cells for the treatment of B cell malignancies. In this review, we focus on the basic structure and current clinical application of CAR-T cells, detail the research progress of CAR-T for different antigenic targets in hematological malignancies, and further discuss the current barriers and proposed solutions, investigating the possible mechanisms of recurrence of CAR-T cell therapy. A summary of the paper is also given to overview as the prospects for this therapy.

20 keywords...

hide…